Publications by authors named "Bala Reddy Bheemareddy"
Article Synopsis
- The study aimed to assess the safety, tolerability, immunogenicity, and efficacy of Bevacizumab in patients with solid tumors across various Indian oncology centers.
- It involved 203 patients and reported a total of 338 adverse events, with the most common being gastrointestinal issues and general disorders; 14 serious adverse events were noted but mostly considered unrelated to the treatment.
- At the end of the study, a small percentage of patients developed antibodies to Bevacizumab, but overall safety and efficacy were not affected, with various levels of tumor response observed among participants.
Background: Recombinant therapeutic anti-CD20 monoclonal antibody (mAb) is used for the treatment of non-Hodgkin's lymphoma, a common B cell lymphoma constituting 80% of all lymphomas. Anti-CD20 mAb contains an Fc-linked biantennary glycan. Although, anti-CD20 monoclonal antibodies are being increasingly used for immunotherapy, their efficacy is limited in a section of patients with drug resistance to immunotherapy.
View Article and Find Full Text PDFFollowing publication of the original article [1], the authors reported errors in the presentation of Tables 2, 4 and 5.
View Article and Find Full Text PDFBackground: Darbepoetin alfa (DA-α) is a long-acting erythropoiesis-stimulating glycoprotein which has half-life three-fold longer than that of Erythropoietin alfa (EPO). The objective of this study was to compare the efficacy and safety of DA-α injection versus EPO for treating renal anemia amongst Indian patients with end-stage renal disease (ESRD) undergoing dialysis.
Methods: Patients of either gender (aged 18-65 years) with ESRD undergoing dialysis who had hemoglobin (Hb) levels < 10 g/dL after receiving EPO were switched to DA-α (0.